Physician profile
Simon Lee
NPI 1275532145
$27,789.92
in general payments reported to CMS, 2019-2025
55 companies · $3,576 in 2025
The $3,576 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,987 · 2020: $3,099 · 2021: $5,041 · 2022: $3,241 · 2023: $3,245 · 2024: $3,599 · 2025: $3,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,421.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,844.87 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $3,486.12 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $3,192.44 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Gilead Sciences, INC. | $2,297.71 | 2019-2025 | Vemlidy, Livdelzi |
| Novo Nordisk INC | $2,181.67 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $1,463.62 | 2019-2025 | Evenity, Otezla, Prolia |
| Lilly USA, LLC | $1,292.64 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $1,093.72 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $901.00 | 2019-2025 | Gardasil 9, Verquvo, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $774.89 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $705.38 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $667.88 | 2020-2025 | Nexletol |
| Pfizer INC. | $639.10 | 2019-2025 | |
| Amarin Pharma, INC. | $504.61 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $471.41 | 2019-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simon Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.